Diffuse esophageal intramural pseudo-diverticulosis (DEIPD) is a chronic fibrosing inflammation of the esophagus of unknown origin. Its name derives from the characteristic pseudo-diverticula formed by dilated ducts of submucosal glands. With an assumed prevalence of approximately 5-50/100 000, DEIPD is more frequent than previously estimated. It preferentially affects men between 50 and 70 years of age with a history of alcohol and tobacco abuse. Key symptoms are chronic dysphagia and food impactions. Typical endoscopic findings are multiple small, longitudinally aligned pseudo-diverticle openings and trachealization of the esophagus. Additionally, the usually gray mucosa may show a fine-grained pattern of very small red dots that merge into a pink tint, called "faux uni pattern." Once established, clinical symptoms and endoscopic changes persist throughout life. Although there is no known causal therapy, complications like bolus impactions, candida infections, or reflux can and should be treated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120889PMC
http://dx.doi.org/10.1002/jgh3.12750DOI Listing

Publication Analysis

Top Keywords

chronic fibrosing
8
diffuse esophageal
8
esophageal intramural
8
intramural pseudo-diverticulosis
8
fibrosing esophagitis
4
esophagitis diffuse
4
pseudo-diverticulosis diffuse
4
pseudo-diverticulosis deipd
4
deipd chronic
4
fibrosing inflammation
4

Similar Publications

Heart failure with preserved ejection fraction (HFpEF) has recently emerged as an insidiously and increasingly prevalent heart failure phenotype. HFpEF often occurs in the context of hypertension and obesity and presents with diastolic dysfunction, ventricular hypertrophy, and myocardial fibrosis. Despite growing study of HFpEF, the causal links between early metabolic changes, bioenergetic perturbations, and cardiac structural remodeling remain unclear.

View Article and Find Full Text PDF

Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).

View Article and Find Full Text PDF

Success of the German Cystic Fibrosis Registry.

Pharmacoepidemiol Drug Saf

January 2025

Mukoviszidose Institut gGmbH, Bonn, Germany.

The German Cystic Fibrosis (CF) Registry (GCFR) is a national General Data Protection Regulation-compliant centralised database sponsored by the German Cystic Fibrosis Association (Mukoviszidose e.V.) and based on informed consent for each participating patient, ethical approval, and data protection votes.

View Article and Find Full Text PDF

Management of primary sclerosing cholangitis: Current state-of-the-art.

Hepatol Commun

December 2024

Division of Gastroenterology and Hepatology, Department of Medicine, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Article Synopsis
  • Primary sclerosing cholangitis is a chronic liver condition associated with inflammation and fibrosis of bile ducts, often linked to inflammatory bowel disease and increases the risk of cancer.
  • Current treatments mainly offer supportive care, as there are no effective medical therapies available and liver transplantation can prolong life but does not cure the disease.
  • Research is ongoing into new therapies aimed at slowing disease progression and alleviating symptoms, with improved trial designs focused on selecting appropriate patients and using better outcome measures to assess treatment effectiveness.
View Article and Find Full Text PDF

Understanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis. TNF-α and IL-13 are key cytokines in Th1 and Th2 immune responses, respectively, while TGF-β1 is the principal pro-fibrotic mediator. We show that 12-day fibroblast culture with TNF-α or IL-13 induces fibrogenesis, marked by progressively increasing type III and VI collagen formation, and that TGF-β1 co-stimulation amplifies these effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!